Clinical trialNCT02301156CompletedPhase 3Interventional

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

SponsorTG Therapeutics, Inc.Enrollment126Chronic Lymphocytic Leukemia

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

This study evaluates the effect of the addition of ublituximab, a novel monoclonal antibody, to ibrutinib compared to ibrutinib alone on antitumor activity, as measured by the overall response rate (ORR = CR \[complete response\] + PR \[partial response\]) in previously treated Chronic Lymphocytic Leukemia (CLL) participants with high-risk cytogenetic features. Half of the participants will receive ublituximab in combination with ibrutinib, while the other half will receive ibrutinib alone.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Jeff Sharman, MD
Willamette Valley Cancer Institute
Study Chair
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

88 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Israel

Tg Therapeutics Investigational Trial Site
Ashkelon, Israel

United States

Tg Therapeutics Investigational Trial Site
Huntsville, Alabama, United States
Tg Therapeutics Investigational Trial Site
Mobile, Alabama, United States
Tg Therapeutics Investigational Trial Site
Chandler, Arizona, United States
Tg Therapeutics Investigational Trial Site
Tucson, Arizona, United States
Tg Therapeutics Investigational Trial Site
Fayetteville, Arkansas, United States
Tg Therapeutics Investigational Trial Site
Jonesboro, Arkansas, United States
Tg Therapeutics Investigational Trial Site
Fullerton, California, United States
Tg Therapeutics Investigational Trial Site
Greenbrae, California, United States
Tg Therapeutics Investigational Trial Site
Los Angeles, California, United States
Tg Therapeutics Investigational Trial Site
Pismo Beach, California, United States
Tg Therapeutics Investigational Trial Site
Pleasanton, California, United States
Tg Therapeutics Investigational Trial Site
Santa Barbara, California, United States
Tg Therapeutics Investigational Trial Site
Aurora, Colorado, United States
Tg Therapeutics Investigational Trial Site
Bridgeport, Connecticut, United States
Tg Therapeutics Investigational Trial Site
Stamford, Connecticut, United States
Tg Therapeutics Investigational Trial Site
Newark, Delaware, United States
Tg Therapeutics Investigational Trial Site
Boca Raton, Florida, United States
Tg Therapeutics Investigational Trial Site
Fort Myers, Florida, United States
Tg Therapeutics Investigational Trial Site
Orange City, Florida, United States
Tg Therapeutics Investigational Trial Site
Pensacola, Florida, United States
Tg Therapeutics Investigational Trial Site
St. Petersburg, Florida, United States
Tg Therapeutics Investigational Trial Site
West Palm Beach, Florida, United States
Tg Therapeutics Investigational Trial Site
Albany, Georgia, United States
Tg Therapeutics Investigational Trial Site
Newnan, Georgia, United States
Tg Therapeutics Investigational Trial Site
Evanston, Illinois, United States
Tg Therapeutics Investigational Trial Site
Maywood, Illinois, United States
Tg Therapeutics Investigational Trial Site
Niles, Illinois, United States
Tg Therapeutics Investigational Trial Site
Urbana, Illinois, United States
Tg Therapeutics Investigational Trial Site
Fort Wayne, Indiana, United States
Tg Therapeutics Investigational Trial Site
Indianapolis, Indiana, United States
Tg Therapeutics Investigational Trial Site
Ames, Iowa, United States
Tg Therapeutics Investigational Trial Site
Cedar Rapids, Iowa, United States
Tg Therapeutics Investigational Trial Site
Westwood, Kansas, United States
Tg Therapeutics Investigational Trial Site
Baton Rouge, Louisiana, United States
Tg Therapeutics Investigational Trial Site
New Orleans, Louisiana, United States
Tg Therapeutics Investigational Trial Site
Baltimore, Maryland, United States
Tg Therapeutics Investigational Trial Site
Baltimore, Maryland, United States
Tg Therapeutics Investigational Trial Site
Bethesda, Maryland, United States
Tg Therapeutics Investigational Trial Site
Columbia, Maryland, United States

48 more sites on the registry record.ClinicalTrials.gov ↗

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Ibrutinib →Ublituximab →

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 27 Jan 2015
Primary completion: 1 Apr 2020
Completion: 1 Apr 2020
Last update posted: 20 May 2022
Registered enrollment: 126
Registry id: NCT02301156

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.